These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36402005)

  • 1. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
    Trummer A; Bethge A; Dickgreber N; Dittrich I; Golpon H; Hoffknecht P; Overbeck TR; Wesseler C; Reck M
    Lung Cancer; 2022 Dec; 174():141-145. PubMed ID: 36402005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
    Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M
    J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
    Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
    Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
    Thorac Cancer; 2023 Apr; 14(11):1004-1011. PubMed ID: 36866788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
    N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
    Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.
    Steendam CMJ; Ernst SM; Badrising SK; Paats MS; Aerts JGJV; de Langen AJ; Dingemans AC
    Lung Cancer; 2023 Jul; 181():107248. PubMed ID: 37216839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
    Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
    Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
    Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
    J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
    Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
    Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
    Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
    Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.